Skip to Content

Corifact Approval History

  • FDA approved: Yes (First approved February 17th, 2011)
  • Brand name: Corifact
  • Generic name: factor XIII concentrate (human)
  • Company: CSL Behring LLC
  • Treatment for: Factor XIII Deficiency

Corifact (factor XIII concentrate (human)) is a is a fibrin-stabilizing factor concentrate indicated to prevent bleeding in people with congenital Factor XIII deficiency.

Development History and FDA Approval Process for Corifact

Feb 17, 2011Approval FDA Approves Corifact to Prevent Bleeding in People With Rare Genetic Defect

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.